Pemantauan Efek Samping Obat Kombinasi Antidiabetes dan Fitofarmaka “X” Pada Pasien DM Tipe-2 di Komunitas

  • Yulianto Universitas Surabaya
  • Lisa Aditama Universitas Surabaya
  • Kartini Kartini Universitas Surabaya
  • Agung Pranoto Universitas Airlangga
Keywords: DM ( Diabetes Melitus), ADR (Adverse Drug Reaction), NGA (New Genetic Alogarithm), (ESO) Efek Samping Obat

Abstract

Pedoman penatalaksanaan DM merekomendasikan  kepatuhan keteraturan gaya hidup dan pengobatan utuk mencapai kontrol glikemik yang baik untuk meminimalkan resiko komplikasi jangka pendek dan jangka panjang. Obat fitofarmaka X yang sedang berkembang sebagai penunjang terapi DM perlu adanya monitoring terkait keamanan terapi kombinasi obat. Penelitian ini menggunakan metode Prospective Cohort Study untuk menilai kausalitas pengaruh terapi kombinasi fitofarmaka X pada kejadian Adverse Drug Reactions (ADR)/ efek samping Obat (ESO) pada pasien DM tipe-2 di Rumah Diabetes UBAYA selama 1 bulan. Penelitian ini menunjukkan bahwa terapi kombinasi obat antidiabetes konvensional + fitofarmaka X mengalami kejadian ESO berupa gejala hipoglikemik (pusing, gemetaran), mual, diare dan dan abdominal discomfort pada pre-post treatment. Efek samping obat yang muncul terkadang tidak dikenali dan dipahami oleh pasien. Untuk itu perlu manajemen yang baik dalam mengelola terapi obat antidiabetes konvensional maupun kombinasi dengan fitofarmaka X pada pasien diabetes mellitus tipe 2 di komunitas

References

[1] Bina D, Komunitas F, Klinik DAN, Jenderal D, Kefarmasian B, Alat DAN, et al. 2005. Pharmaceutical care untuk penyakit diabetes mellitus. 1–85 p.
[2] Perkeni. 2015. Konsensus Pengendalian dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia 2015. Perkeni. 78 p.
[4] Yusuff KB, Obe O, Joseph BY. 2008.Adherence to anti-diabetic drug therapy and self management practices among type-2 diabetics in Nigeria. Pharm World Sci 30:876–83.
[5] Kemenkes RI. 2011. Formularium Obat Herbal Asli Indonesia. Jakarta: Kementrian Kesehatan RI. 219 p.
[6] Permenkes RI. 2017. Pelayanan Kesehatan Tradisional Integrasi.
[7] Elements P. 1993. ASHP Statement on Pharmaceutical Care. 270–2
[8] Robert J. Cipolle, Strand LM, J PCM. 2004. Pharmaceutical Care Practice The Clinician’s Guide. 1–624 p.
[9] Perkeni. 2011. Konsensus Pengendalian dan Pencegahan Diabetes Mellitus Tipe 2 di Indonesia 2011. 1–72 p.
[10] Riddle MC, Bakris G, Blonde L, Boulton AJM, D ’alessio D, De Groot M, et al. 2018-ADA-Standards-of-Medical Care in Diabetes. J Clin Appl Res Educ. 41(1).
[11] Sastroasmoro PD dr. S, Ismael P dr. S . 2014. Dasar-dasar Metodologi Penelitian Klinis. Edisi 5. Jakarta: Sagung Seto364–365 p.
[12] Edwards IR, Aronson JK. 2000. Adverse drug reactions Adverse drug reactions?: definitions , diagnosis , and management. Lancet. 356:1255–9.
[13] FDA. 2017.The FDA’s Drug Review Process: Ensuring Drugs Are Safe and Effective [Internet]. US Department Health and Human Services. Available from: https://www.fda.gov/drugs/resourcesforyou/consumers/ucm143534.htm
[14] Koh Y, Wei C, Chuen S. 2007. A quantitative approach of using genetic algorithm in designing a probability scoring system of an adverse drug reaction assessment system. 7:421–30.
[15] Stephanie N. Schartz RJW. . 2015. Adverse drug reactions. PSAP 5–26.
[16] Alomar MJ. . 2015. Factors affecting the development of adverse drug reactions (Review article). Saudi Pharm J. King Saud University 22(2):83–94.
[17] Prospective UK, Study D. 1998. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. 352(Ukpds 34).
[18] Prospective UK, Study D. 1998. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes ( UKPDS 33 ). 352(Ukpds 33):837–53.
[19] Cryer P.E. 2013. Hypoglycemia-associated autonomic failure in diabetes. Handb Clin Neurol. 1115–21
[20] Cryer PE, Davis SN, Harry Shamoon. 2003. Hypoglycemia in Diabetes. Diabetes Care. 26(6):1902–12.
[21] Fatima M, Sadeeqa S, Nazir SUR. 2018. Metformin and its gastrointestinal problems: A review. Biomed Res. 29(11):2285–9.
[22] McCreight LJ, Bailey CJ, Pearson ER. 2016. Metformin and the gastrointestinal tract. Diabetologia. 59(3):426–35.
[23] Ulbricht C, Seamon E, Windsor RC, Armbruester N, Bryan JK, Costa D, et al. . 2011. An evidence-based systematic review of cinnamon (Cinnamomum spp.) by the natural standard research collaboration. J Diet Suppl8(4):378–454.
[24] Kiss AK1 PJ. 2018. Ellagitannins, Gallotannins and their Metabolites- The Contribution to the Anti-Inflammatory Effect of Food Products and Medicinal Plants. pubmed.gov. p. 1.
Published
2020-01-16